“This is exactly what we need as part of our go-to-market strategy. We need patients to be able to see they’re doing better on a new treatment than they were before.”

“The relative benefit of Folia to a drug increases as you start early. This is true disseminated data capture; decentralized trials are a tactical component of that overall strategy. You’re adding to, not taking away from, claims & clinical data. Pharma would prefer a single source of truth, and you’re moving us in that direction.”

“This is important. Clinical trials use narrowly defined populations that are supposed to be representative. But the inclusion criteria are very specific. They therefore don’t get a good grasp of comorbidities or which patients may respond to treatment best.”